Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey
Abstract Background Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin therapy use among patients at intermediate risk according to...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-024-03388-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846158841505382400 |
|---|---|
| author | Anjali Vaidya Margaret R. Sketch Meredith Broderick Oksana A. Shlobin |
| author_facet | Anjali Vaidya Margaret R. Sketch Meredith Broderick Oksana A. Shlobin |
| author_sort | Anjali Vaidya |
| collection | DOAJ |
| description | Abstract Background Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin therapy use among patients at intermediate risk according to the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 2.0 four-strata risk assessment model. Methods This was a retrospective chart review and cross-sectional online survey of healthcare professionals (HCPs). Included patients were classified as intermediate-low or intermediate-high risk per COMPERA 2.0 between 2016 and 2020 (index visit), initiated on a parenteral prostacyclin any time following intermediate risk assessment, and had World Health Organization (WHO) Functional Class (FC), 6-minute walk distance (6MWD), and B-type natriuretic peptide/N-terminal pro B-type natriuretic peptide (BNP/NT-proBNP) assessments at index and first comprehensive follow-up visits (follow-up). Results A total of 139 HCPs (53% community-based, 47% Pulmonary Hypertension Care Center-based) participated in the survey and provided 350 patient records; among these, mean age (SD) was 54.1 (15.3) years and 52% were female. Median (IQR) time from parenteral prostacyclin initiation to follow-up was 3.0 months (2.0, 7.0). At parenteral prostacyclin initiation for the 280 patient records with available COMPERA 2.0 assessments, 62% of patients were intermediate-high risk, 33% were intermediate-low risk and 3% were low risk, improving to 38%, 53%, and 8%, respectively, at follow-up. Conclusions Improvements were seen for the individual COMPERA 2.0 risk calculator parameters and for several other clinical parameters. Findings from this study substantiate recent guidelines suggesting earlier use of this treatment in intermediate-risk patients with PAH. Clinical trial number Not applicable. |
| format | Article |
| id | doaj-art-d21c1441f55344fea0f2c81cf05617e0 |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-d21c1441f55344fea0f2c81cf05617e02024-11-24T12:08:55ZengBMCBMC Pulmonary Medicine1471-24662024-11-0124111510.1186/s12890-024-03388-wParenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional surveyAnjali Vaidya0Margaret R. Sketch1Meredith Broderick2Oksana A. Shlobin3Temple University Lewis Katz School of MedicineUnited Therapeutics CorporationUnited Therapeutics CorporationInova Fairfax Hospital, University of Virginia School of MedicineAbstract Background Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin therapy use among patients at intermediate risk according to the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) 2.0 four-strata risk assessment model. Methods This was a retrospective chart review and cross-sectional online survey of healthcare professionals (HCPs). Included patients were classified as intermediate-low or intermediate-high risk per COMPERA 2.0 between 2016 and 2020 (index visit), initiated on a parenteral prostacyclin any time following intermediate risk assessment, and had World Health Organization (WHO) Functional Class (FC), 6-minute walk distance (6MWD), and B-type natriuretic peptide/N-terminal pro B-type natriuretic peptide (BNP/NT-proBNP) assessments at index and first comprehensive follow-up visits (follow-up). Results A total of 139 HCPs (53% community-based, 47% Pulmonary Hypertension Care Center-based) participated in the survey and provided 350 patient records; among these, mean age (SD) was 54.1 (15.3) years and 52% were female. Median (IQR) time from parenteral prostacyclin initiation to follow-up was 3.0 months (2.0, 7.0). At parenteral prostacyclin initiation for the 280 patient records with available COMPERA 2.0 assessments, 62% of patients were intermediate-high risk, 33% were intermediate-low risk and 3% were low risk, improving to 38%, 53%, and 8%, respectively, at follow-up. Conclusions Improvements were seen for the individual COMPERA 2.0 risk calculator parameters and for several other clinical parameters. Findings from this study substantiate recent guidelines suggesting earlier use of this treatment in intermediate-risk patients with PAH. Clinical trial number Not applicable.https://doi.org/10.1186/s12890-024-03388-wRetrospective studiesProstacyclinsProstaglandinsRisk assessmentPulmonary hypertension |
| spellingShingle | Anjali Vaidya Margaret R. Sketch Meredith Broderick Oksana A. Shlobin Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey BMC Pulmonary Medicine Retrospective studies Prostacyclins Prostaglandins Risk assessment Pulmonary hypertension |
| title | Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey |
| title_full | Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey |
| title_fullStr | Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey |
| title_full_unstemmed | Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey |
| title_short | Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey |
| title_sort | parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate risk strata a retrospective chart review and cross sectional survey |
| topic | Retrospective studies Prostacyclins Prostaglandins Risk assessment Pulmonary hypertension |
| url | https://doi.org/10.1186/s12890-024-03388-w |
| work_keys_str_mv | AT anjalivaidya parenteralprostacyclinutilizationinpatientswithpulmonaryarterialhypertensionintheintermediateriskstrataaretrospectivechartreviewandcrosssectionalsurvey AT margaretrsketch parenteralprostacyclinutilizationinpatientswithpulmonaryarterialhypertensionintheintermediateriskstrataaretrospectivechartreviewandcrosssectionalsurvey AT meredithbroderick parenteralprostacyclinutilizationinpatientswithpulmonaryarterialhypertensionintheintermediateriskstrataaretrospectivechartreviewandcrosssectionalsurvey AT oksanaashlobin parenteralprostacyclinutilizationinpatientswithpulmonaryarterialhypertensionintheintermediateriskstrataaretrospectivechartreviewandcrosssectionalsurvey |